30 reports of this reaction
2.4% of all DEXTROMETHORPHAN POLISTIREX reports
#6 most reported adverse reaction
HYPERSENSITIVITY is the #6 most commonly reported adverse reaction for DEXTROMETHORPHAN POLISTIREX, manufactured by Haleon US Holdings LLC. There are 30 FDA adverse event reports linking DEXTROMETHORPHAN POLISTIREX to HYPERSENSITIVITY. This represents approximately 2.4% of all 1,242 adverse event reports for this drug.
Patients taking DEXTROMETHORPHAN POLISTIREX who experience hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERSENSITIVITY is a less commonly reported adverse event for DEXTROMETHORPHAN POLISTIREX, but still significant enough to appear in the safety profile.
In addition to hypersensitivity, the following adverse reactions have been reported for DEXTROMETHORPHAN POLISTIREX:
The following drugs have also been linked to hypersensitivity in FDA adverse event reports:
HYPERSENSITIVITY has been reported as an adverse event in 30 FDA reports for DEXTROMETHORPHAN POLISTIREX. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERSENSITIVITY accounts for approximately 2.4% of all adverse event reports for DEXTROMETHORPHAN POLISTIREX, making it a notable side effect.
If you experience hypersensitivity while taking DEXTROMETHORPHAN POLISTIREX, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.